All In Biotech

Drug Trial Radar · NCT07112378

A Study of Dupilumab in Small Children With an Allergic Condition of the Esophagus (Food Pipe): Eosinophilic Esophagitis

A Randomized Study Evaluating 2 Dose Regimens of Dupilumab in Children ≥6 Months of Age Weighing ≥5 to <15 kg With Active Eosinophilic Esophagitis

Last checked: Nov 20, 2026Latest source record: Sep 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

20

Planned (sponsor's estimate)

Start

Nov 10, 2025

Primary completion

Jun 19, 2028

Study completion Oct 9, 2028

Sponsor

Lead sponsor
Regeneron PharmaceuticalsRegeneron (REGN)
Sponsor type
Industry
Collaborators
Sanofi
First posted
Aug 8, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Single (care provider)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 6 months, up to 6 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is researching an experimental drug called dupilumab (called "study drug"). The study is focused on children with active eosinophilic esophagitis (EoE; an inflammatory disease of the esophagus) which impacts feeding and nourishment. The aim of the study is to see how safe, tolerable, and effective the study drug is when given for 24 weeks to children with active EoE. The study is looking at several other research questions, including: * What side effects may happen from taking the study drug * How much study drug is in the blood at different times * Whether the body makes antibodies against the study drug (which could make the drug less effective or could lead to side effects)

Conditions

  • Eosinophilic Esophagitis (EoE)

Interventions

  • dupilumabDrug

    Administered as defined in the protocol

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of treatment-emergent Serious Adverse Events (SAEs)Time frame: Up to 24 Weeks

Locations

13 sites in 1 country. Site status is shown where the registry gives one.

  • Phoenix Childrens Hospital

    Phoenix, Arizona · Recruiting

  • University of California San Francisco (UCSF)

    San Francisco, California · Recruiting

  • Children's Hospital Colorado

    Aurora, Colorado · Recruiting

  • GI Care for Kids LLC

    Atlanta, Georgia · Recruiting

  • Massachusetts General Hospital

    Boston, Massachusetts · Recruiting

  • Weill Cornell Medicine

    New York, New York · Recruiting

  • University of North Carolina, Bioinformatics Building

    Chapel Hill, North Carolina · Recruiting

  • Children's Hospital of Philadelphia

    Philadelphia, Pennsylvania · Recruiting

  • Medical University of South Carolina

    Charleston, South Carolina · Recruiting

  • Cook Children's Medical Center

    Fort Worth, Texas · Recruiting

  • University of Virginia

    Charlottesville, Virginia · Recruiting

  • Seattle Children's Hospital

    Seattle, Washington · Recruiting

  • Medical College of Wisconsin, Children's Hospital of Wisconsin

    Milwaukee, Wisconsin · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.